NIVOLUMAB

Brand name:

• Opdivo®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Submission sponsor:

Bristol-Myers Squibb Australia Pty Ltd

Condition/indication:
(therapeutic use)

• Advanced or metastatic oesophageal squamous cell carcinoma

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC Submission type:

Change to listing (–)

Comment:

Non-submission item

Other PBAC consideration:

• NIVOLUMAB

Submission received for:

July 2023 PBAC meeting

Opportunity for consumer comment:

Open 29/03/2023 and close 24/05/2023 (see PBS Website)

PBAC meeting:

Held on 05/07/2023

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

05/09/2023

Lodgement of required documentation:

15/09/2023

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 31/10/2023

Status:

Finalised

Government processes:

Commenced on 31/10/2023

Medicine listed on the PBS:

01/12/2023 (see PBS schedule)